trial

Translational Neuroscience Optimization of GlyT1 Inhibitor

NCTId NCT01911676
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 71 (actual)
Sponsored by Yale University
Primary completion 2018-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
71 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2013-08
Primary completion
2018-12
Eligibility
ALL · 21 Years · 65 Years

Interventions & indications

Drugs
PF-03463275

Sponsors

Yale UniversityLead Sponsor
National Center for Advancing Translational Sciences (NCATS)Collaborator

Investigators

1
Deepak Cyril D'Souza, MDPrincipal Investigator

Sites

2 total
New Haven, United StatesWest Haven, United States

Linked catalysts

1
Translational Neuroscience Optimization of GlyT1 Inhibitor — primary completion2018-12

Facts & assertions

4 sourced
Enrollment
71
Phase
PHASE2
Primary Completion Date
2018-12
Status
COMPLETED
relationships
The graph out of here
drug
PF-03463275
drug
lead_sponsor
Yale University
company
collaborator
National Center for Advancing Translational Sciences (NCATS)
company
indication
Cognitive Impairments Associated With Schizophrenia
indication
investigator
Deepak Cyril D'Souza, MD
person